ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AUM Biosciences has raised $27 million in series A funding to develop small-molecule therapies for genetically defined cancers. The Singapore-based start-up will use the funds to begin Phase 2 clinical trials of its lead programs: an inhibitor that targets the kinase MNK and a molecule that targets tumors that have TRK fusions. AUM is also developing a PI3K kinase inhibitor that it says could be useful in combating drug resistance in tumors.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter